Complete financial analysis of Pharmaxis Ltd (PMXSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmaxis Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- AJ Advance Technology Public Company Limited (AJA.BK) Income Statement Analysis – Financial Results
- LIAONING ENERGY INDUSTRY Co.,LTD (600758.SS) Income Statement Analysis – Financial Results
- LIG Assets, Inc. (LIGA) Income Statement Analysis – Financial Results
- China Fortune Financial Group Limited (0290.HK) Income Statement Analysis – Financial Results
- Jinhong Holding Group Co., Ltd. (000669.SZ) Income Statement Analysis – Financial Results
Pharmaxis Ltd (PMXSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharmaxis.com.au
About Pharmaxis Ltd
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 8.63M | 6.74M | 17.00M | 4.84M | 3.98M |
| Cost of Revenue | 10.58M | 11.29M | 11.59M | 11.10M | 11.17M |
| Gross Profit | -1.95M | -4.55M | 5.42M | -6.26M | -7.19M |
| Gross Profit Ratio | -22.64% | -67.52% | 31.85% | -129.36% | -180.50% |
| Research & Development | 5.80M | 4.98M | 3.58M | 4.37M | 6.08M |
| General & Administrative | 15.52M | 14.08M | 14.87M | 14.47M | 0.00 |
| Selling & Marketing | 305.00K | 755.00K | 1.47M | 1.35M | 0.00 |
| SG&A | 3.95M | 4.20M | 5.14M | 3.75M | 3.93M |
| Other Expenses | 14.03M | 7.22M | 17.99M | 5.00M | 0.00 |
| Operating Expenses | 9.75M | 9.19M | 8.72M | 8.11M | 10.01M |
| Cost & Expenses | 20.33M | 20.48M | 20.31M | 19.21M | 21.18M |
| Interest Income | 77.92K | 9.39M | 37.54K | 1.74M | 637.89K |
| Interest Expense | 148.52K | 0.00 | 277.03K | 0.00 | 167.02K |
| Depreciation & Amortization | -1.23M | -2.23M | -2.37M | -2.23M | -2.00M |
| EBITDA | -10.47M | -11.50M | -937.69K | -12.14M | -15.36M |
| EBITDA Ratio | -121.38% | -170.70% | -5.52% | -251.02% | -385.57% |
| Operating Income | -11.70M | -13.74M | -3.30M | -14.37M | -17.20M |
| Operating Income Ratio | -135.64% | -203.86% | -19.43% | -297.07% | -431.71% |
| Total Other Income/Expenses | 344.95K | 11.80M | 18.94M | 429.47K | -1.06M |
| Income Before Tax | -11.06M | -4.72M | -2.34M | -13.15M | -18.26M |
| Income Before Tax Ratio | -128.16% | -70.00% | -13.77% | -271.84% | -458.42% |
| Income Tax Expense | -3.49M | -3.38M | -111.11K | -3.55M | -4.18M |
| Net Income | -7.57M | -1.34M | -2.23M | -9.60M | -14.08M |
| Net Income Ratio | -87.67% | -19.82% | -13.11% | -198.42% | -353.38% |
| EPS | -0.01 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 655.62M | 562.90M | 407.28M | 394.74M | 381.39M |
| Weighted Avg Shares Out (Dil) | 655.62M | 562.90M | 407.28M | 394.74M | 381.39M |
Source: https://incomestatements.info
Category: Stock Reports